Dr. Victor Oyervides-Juarez

Profesor de Oncologia Medica en Hospital Universitario, UANL
Oncare Cancer Center

[Summit Therapeutics @SMMT_TX]

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over the Closing Trading Price

Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers

Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines

https://t.co/Xp5DCiJFmI

[Balazs Halmos @BalazsHalmosMD]

I heard AstraZeneca renamed this exciting vegf/pd1 bispecific to iwantescimab😉

[Tom Powles @tompowles1]

AZ are linking with Summit Therapeutics to develop Ivonescimab (VEGF/PD1 bispecific), particularly ADC combos. This promising area of development is moving rapidly. This link will accelerate things further. Robust global data outside of lung cancer is eagerly awaited. @OncoAlert @myESMO @Annals_Oncology https://t.co/41dIbkFfBD

[Hidehito HORINOUCHI @HHorinouchi]

🔥INTerpath-001: "Statistically significant and clinically meaningful improvements in RFS and DMFS"
🆙 @Merck @moderna_tx
👥Patients: Completely resected stage IIB-IV cutaneous melanoma, no prior systemic therapy
3⃣Phase III
⚖️Intismeran autogene (mRNA-4157) + pembrolizumab
⚖️Pembrolizumab alone (+ placebo)
🔢NCT05933577
@OncoAlert @Larvol
🔗 https://t.co/gwh3BHxVNI

[Toni Choueiri, MD @DrChoueiri]

JUST IN and via @Merck + @moderna_tx: A landmark moment for cancer immunotherapy. 🎯

Phase 3 INTerpath-001 is positive: the individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) + pembrolizumab significantly improved both RFS/DMFS vs pembrolizumab alone after resection of high-risk melanoma.

For years, the idea of designing a treatment around the unique mutations of each patient’s tumor seemed aspirational. Now we have the first positive Phase 3 trial (N=1137) of an individualized neoantigen therapy—and of an mRNA-based cancer therapy.

Personalized cancer vaccines are moving from promise to reality.

Now we need to see the magnitude of benefit, durability, and ultimately OS. But today is an important day for the field—and hopefully for our patients. 👏

Congrats to #CathyWu @DanaFarber for her trailblazing research that is materializing in tangible outcomes! At @DanaFarber_GU we are closely working with Cathy + @DFCI_NeoVax team on several GU protocols, after our @Nature work with @BraunMDPhD et al (https://t.co/BdbKJqMKOw)

https://t.co/Akd0XQt3ml

[Oncology Brothers @OncBrothers]

8 new drugs/indications were approved by @FDAOncology for Thoracic Malignancies in 2021!

We have created tables for indications and their results to stay organized and for a quick reference.

#MedTwitter @OncoAlert #OncTwitter #LCSM @IASLC #lungcancer #thyroidcancer

[Centro Universitario Contra el Cancer UANL @CUCCUANL]

El Centro Universitario Contra el Cáncer UANL les desea a todos una Feliz Navidad en compañía de sus seres queridos

@fmuanl @posgradofmuanl @uanl

[Gil Morgan, MD @weoncologists]

Gotta love these @JAMAOnc Patient Page📰

#immunotherapy 💉Adverse Effects

1️⃣in5️⃣patients on immunotherapy will have an irAE

Things that increase risk include using2️⃣🧪immunotherapy drugs at the same time & having a history of autoimmune disease 🦠

https://t.co/sY8MS9rgvT

[John Suh @DrJohnSuh]

Terrific update from @ShaunaRadOnc @CleClinicMD on head and neck tumors during the 23rd Annual Best of Radiation Oncology #radonc course @ARRO_org @DrSpratticus @RadoncUh @caseccc #CleClinicCancer

[Christian Rolfo @ChristianRolfo]

Welcoming to #LALCA21 from LATAM Chair @LuisERaez1 and our @IASLC President @HwakeleeMD. Great agenda and faculty. Don’t miss it! https://t.co/0tMSvE62BM

[Centro Universitario Contra el Cancer UANL @CUCCUANL]

17 de Noviembre 🤍, día Internacional de la Lucha Contra el Cáncer Pulmonar.

¡No lo dejes pasar y averigua aquí el riesgo de padecer esta enfermedad!

Juntos podemos prevenir, detectar oportunamente y tratar con éxito el cáncer.
🔽🔽🔽
https://t.co/cCnaKHbK8B

@fmuanl @uanl

[Centro Universitario Contra el Cancer UANL @CUCCUANL]

Tenemos el honor de invitarlos al "Congreso Universitario de Cáncer de Pulmón", a llevarse a cabo el 17 de Noviembre a partir de las 9:00 hrs en modalidad híbrida. Link de Registro:
https://t.co/KCP41BPbso

@fmuanl @uanl @drvmoyervides @DrSalazarMejia @ogarrieta @AndresFCardonaZ

[Heather Wakelee @HwakeleeMD]

Very happy to see the FDA approval of adjuvant atezolizumab in patients with resected PD-L1+ early stage NSCLC. So excited to have been a part of the practice changing IMpower010 trial! Making a difference in the lives of NSCLC patients! #LCSM

[Dr. Iván R. González @Dr_Ivanoncologo]

This #article explore the preclinical and pharmacological differences between palbociclib, ribociclib and abemaciclib💡and help us understand the benefits seen with these agents in certain subgroups of patients with metastatic HR positive #breastcancer👏📑
Interesting to read🤩

[Dr. Victor Oyervides-Juarez @drvmoyervides]

@AndresFCardonaZ El Mayor de los Exitos Andres @AndresFCardonaZ

[Mohamed A Gouda @mgoudaMD]

#ESMO21 is starting in few hours!
I am glad to be presenting our work on the use of #LiquidBiopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer (Poster 91P). See you tomorrow :)

[FabriceAndre @FAndreMD]

Clinical definition of acquired resistance ti anti-PD1 Ab inpts with metastatic NSCLC: 4 criteria and 3 area for exploration https://t.co/jhfYvBJ0NY

[Alec Stone @AlecJStone]

NIH study illuminates origins of lung cancer in never smokers https://t.co/KbfYV6Qvka

[Dr. Victor Oyervides-Juarez @drvmoyervides]

Melanoma Mucosa Irresecable @drvmoyervides @DaneliRT @nattvb1 @adolfomontemayor

[Dr. Victor Oyervides-Juarez @drvmoyervides]

Las mejor decision terapeutica con el Mejor Equipo: Tumor Board Cancer de Cabeza y Cuello Melanoma Mucosa @drvmoyervides @CUCCUANL @Radiologia_HU @fmuanl